Orion to use Aitia’s ‘digital twins’ to identity potential new cancer drugs
Finnish biotech Orion has spied potential in Aitia’s “digital twin” tech to develop new cancer drugs.
All Posts in "News Team"
Windtree’s cardiogenic shock med raises blood pressure in latest phase 2 win
While Windtree Therapeutics has struggled to grow the financial roots needed to survive, a phase 2 win for the biotech’s lead asset will at least give the company encouragement to persevere.
Merck’s Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. The drugmaker found a fixed-dose combination of Keytruda and an anti-LAG-3 antibody failed to improve overall survival, extending the wait for a checkpoint inhibitor that moves the needle in the indication.
New PicnicHealth service brings observational clinical trial research to the virtual world
Health tech company PicnicHealth is launching a new program that lets researchers conduct clinical trials in cyberspace. Virtual Site is meant to help clinical trial sponsors conduct observational studies without the need for a physical location.
OncoC4 founders take own science under their wing in new biotech merger
OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger.
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic.
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the anti-OX40 antibody to significant improvements in symptoms. But, while the trial met its primary endpoints, the biotech still needs to make the case that there is a role for rocatinlimab in a market served by Dupixent.
Clinical trial site network Headlands Research opens new location in El Paso, Texas
Headlands Research, a clinical trial site network with locations across the U.S. and Canada, is launching its newest site on the U.S.-Mexico border in El Paso, Texas.
NewHold Investment Corp. III Files to Offer Up to 20M Units in IPO
NewHold Investment Corp. III filed to offer up to almost 20.1 million units in its initial public offering.
Lululemon longtime bear is still telling investors to sell the stock
Stock is trading at its second relative high versus Nike in a year, making it look overvalued, analyst says
Weekly Market Review – January 25, 2025
Weekly Market Review – January 18, 2024
Weekly Market Review – January 11, 2025
Weekly Market Review – January 11, 2025
Weekly Market Review – January 4, 2025
Orion to use Aitia’s ‘digital twins’ to identity potential new cancer drugs
Windtree’s cardiogenic shock med raises blood pressure in latest phase 2 win
Merck’s Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
New PicnicHealth service brings observational clinical trial research to the virtual world
OncoC4 founders take own science under their wing in new biotech merger